Sharon Benzeno Adaptive Biotechnologies Corp (ADPT) insider trading activity

Sharon Benzeno is Chief Commercial Ofc Imm Med of Adaptive Biotechnologies Corp. Currently has a direct ownership of 327,415 shares of ADPT, which is worth approximately $1.16 Million. The most recent transaction as insider was on Mar 05, 2024, when has been sold 29,390 shares (Common Stock) at a price of $3.44 per share, resulting in proceeds of $101,101. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 327K

0% 3M change

46.28% 12M change

Total Value Held $1.16 Million

SHARON BENZENO Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2024	SELL Open market or private sale	$101,101 $3.44 p/Share	29,390 Reduced 8.24%	327,415 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	132,979 Added 27.15%	356,805 Common Stock
Mar 06 2023	SELL Open market or private sale	$100,688 $8.57 p/Share	11,749 Reduced 4.99%	223,826 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	132,979 Added 36.08%	235,575 Common Stock
Mar 07 2022	SELL Open market or private sale	$32,067 $12.01 p/Share	2,670 Reduced 2.54%	102,596 Common Stock
Mar 04 2022	BUY Grant, award, or other acquisition	-	82,372 Added 43.9%	105,266 Common Stock
Mar 15 2021	SELL Open market or private sale	$56,245 $41.54 p/Share	1,354 Reduced 5.58%	22,894 Common Stock

Mar 15 2021	BUY Exercise of conversion of derivative security	$42,935 $31.71 p/Share	1,354 Added 5.29%	24,248 Common Stock
Mar 04 2021	BUY Grant, award, or other acquisition	-	22,894 Added 50.0%	22,894 Common Stock
Mar 01 2021	SELL Open market or private sale	$391,838 $57.87 p/Share	6,771 Reduced 100.0%	0 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	$45,975 $6.79 p/Share	6,771 Added 50.0%	6,771 Common Stock
Feb 19 2021	SELL Open market or private sale	$25,459 $61.2 p/Share	416 Reduced 100.0%	0 Common Stock
Feb 19 2021	BUY Exercise of conversion of derivative security	$2,608 $6.27 p/Share	416 Added 50.0%	416 Common Stock
Feb 16 2021	SELL Open market or private sale	$1,046,988 $64.43 p/Share	16,250 Reduced 100.0%	0 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$515,287 $31.71 p/Share	16,250 Added 50.0%	16,250 Common Stock
Feb 01 2021	SELL Open market or private sale	$379,188 $56.01 p/Share	6,770 Reduced 100.0%	0 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$45,968 $6.79 p/Share	6,770 Added 50.0%	6,770 Common Stock
Jan 19 2021	SELL Open market or private sale	$28,773 $69.0 p/Share	417 Reduced 100.0%	0 Common Stock
Jan 19 2021	BUY Exercise of conversion of derivative security	$2,615 $6.27 p/Share	417 Added 50.0%	417 Common Stock
Jan 04 2021	SELL Open market or private sale	$392,786 $58.01 p/Share	6,771 Reduced 100.0%	0 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$45,975 $6.79 p/Share	6,771 Added 50.0%	6,771 Common Stock
Dec 21 2020	SELL Open market or private sale	$24,661 $59.14 p/Share	417 Reduced 100.0%	0 Common Stock
Dec 21 2020	BUY Exercise of conversion of derivative security	$2,615 $6.27 p/Share	417 Added 50.0%	417 Common Stock
Dec 01 2020	SELL Open market or private sale	$330,511 $48.82 p/Share	6,770 Reduced 100.0%	0 Common Stock
Dec 01 2020	BUY Exercise of conversion of derivative security	$45,968 $6.79 p/Share	6,770 Added 50.0%	6,770 Common Stock

Sharon Benzeno

Chief Commercial Ofc Imm Med

Seattle, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Value

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT

Account